# OnCo record nct03800134 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03800134/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03800134", "NCT03800134" ;
  schema:name "A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer"@en ;
  schema:alternateName "AEGEAN"@en ;
  schema:description "A phase 3 trial of Durvalumab, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03800134/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03800134>, <https://doi.org/10.1200/JCO-25-02659>, <https://www.nice.org.uk/guidance/ta1030> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2018-12-06" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:trials <https://onco.cc/trials/checkmate-816/>, <https://onco.cc/trials/keynote-671/>, <https://onco.cc/trials/nct04025879/>, <https://onco.cc/trials/neotorch/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/> .